SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros much-better-than-expected quarterly results and raised outlook, attributed to strong AI-server demand, are driving attention. Bulls see the shares as undervalued and anticipate a rerating, while others are frustrated by the muted reaction and cite thin margins, cash-flow and inventory concerns, and lingering doubts about management credibility.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs better-than-expected quarterly results and stronger outlook, driven by surging AI and data-center demand, are fueling a sharp rally and optimism about continued growth. Some traders remain wary of valuation, weaker cash flow and margin concerns, and the companys growing reliance on data-center spending, with debate over whether the gains will hold.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Attention centers on the U.S. midterm elections and shifting expectations for control of Congress, with traders debating whether a Democratic wave and a weakened Trump administration could weigh on DJT or whether Republican gains would support the stock. The discussion is highly polarized, and election outcomes and their market impact remain uncertain.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs strong quarterly results and raised outlook are drawing attention, but the shares have sold off despite the beat. Traders are split between bullish views on AI-data-center connectivity demand and concerns about the stocks rich valuation, possible margin pressure, and whether AI spending expectations are already priced in.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Aristas quarterly results beat expectations and its next-quarter outlook was stronger than anticipated, with traders pointing to demand for AI data-center networking. The reaction is broadly bullish, though some are debating whether the sharp post-earnings move can hold amid valuation concerns and potential profit-taking.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Attention centers on CCXIs Agility Robotics and humanoid-robotics story, with traders drawing bullish comparisons to Unitrees high-profile IPO and reacting to reports of possible U.S. restrictions on Chinese-made robots. Optimists see a sector tailwind and potential squeeze, while skeptics point to SPAC risks, valuation, losses, and uncertainty about commercial scaling.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on a letter from 28 HOPE-3 investigators urging FDA approval of deramiocel for non-ambulatory Duchenne muscular dystrophy, ahead of the agencys Nov. 22 decision. Many traders view the letter as strengthening the case and cite short-covering as a possible contributor to the rally, while others remain cautious about the FDAs prior statistical concerns and the binary decision risk.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters quarterly results and raised fourth-quarter revenue outlook are driving discussion, with traders highlighting strong growth and improving losses while questioning softer gross margins and whether the outlook supports continued expansion. Reactions are split between optimism about lidar demand in robotics and Physical AI and concern over the stocks volatility and broader pressure on growth shares.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevras Q3 results, including an earnings beat and plans to seek a MIPLYFFA label expansion for infants, are driving discussion. Many traders view the results, U.S. product growth and cash position as undervalued, while others are frustrated by the muted share-price reaction and debate whether a sale or regulatory progress is needed to unlock value.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos quarterly earnings and raised full-year guidance are driving attention, with traders pointing to accelerating daily-user growth and stronger-than-expected revenue while also noting an EPS miss. The reaction is divided: bulls see user growth and guidance as encouraging, while bears remain concerned about valuation, monetization, and AI competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the...

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences Citius Pharmaceuticals to Participate in October 2026 Investor ConferencesPR NewswireCRANFORD, N.J., Oct. 12, 2026Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth...

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences Citius Pharmaceuticals to Participate in September 2026 Investor Conferences PR Newswire CRANFORD, N.J., Sept. 3, 2026 Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 Million in revenue for the first...

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 million in revenue for the first nine months...

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri PR Newswire CRANFORD, N.J., Aug. 12, 2026 CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology...

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment PR Newswire CRANFORD, N.J., Aug. 5, 2026 New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal...

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire CRANFORD, N.J., July 21, 2026 Expanded...

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Citius Oncology Inc.

Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>FDA approved Lymphir for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma.</li><li>Phase 3 data showed a 36.2% response rate, with most patients seeing reduced skin tumor burden.</li><li>Lymphir is available nationwide with a permanent J-code effective April to support reimbursement.</li></ul>Citius Oncology (CTOR) said on Monday it has launched&nbsp;Lymphir, a newly approved cancer immunotherapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL), making the drug available nationwide through specialty distributors.The U.S. Food and Drug Administration (FDA) approved Lymphir, also known as denileukin diftitox-cxdlfor adults with cutaneous T-cell lymphoma, a form of skin cancer that can cause painful, itchy lesions. The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.The stock jumped nearly 18% to $1.62 at the time of writing.&nbsp;<h2 class="st-heading-2">Clinical Findings</h2>The immunotherapy approval was supported by results from Phase 3 Study 302, which reported an objective response rate of 36.2%. According to Citius, 84% of evaluable patients saw reductions in skin tumor burden, and the median time to response was 1.4 months. The company said the therapy was not associated with cumulative toxicity.Lymphir is the first FDA-approved systemic therapy for CTCL in more than seven years. It has been added to the National Comprehensive Cancer Network guidelines with a Category 2A recommendation, meaning the therapy is recommended, with uniform agreement from experts.&nbsp;<h2 class="st-heading-2">Commercial Rollout&nbsp;</h2>Lymphir has a permanent J-code, effective since April, to support reimbursement. Citius is providing medical education, payer-access support and a patient assistance program, which includes reimbursement and benefits guidance as well as prior authorization support.&nbsp;<h2 class="st-heading-2">Global Expansion Plans&nbsp;</h2>Outside the U.S., Citius holds rights to develop and commercialize Lymphir in all markets except India, Japan and certain parts of Asia. The company recently signed a distribution agreement with Integris Pharma to begin named-patient access programs in Greece, Cyprus and other Southern European and Balkan countries.<h2 class="st-heading-2">Stocktwits Users Turn ‘Extremely Bullish’</h2>On Stocktwits, retail sentiment for Citius Oncology turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/ctor_ss_png_c597304fdc.webp" alt="ctor ss.png" width="969" height="142"><figcaption>CTOR sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure>One bullish user said, “interesting to see what happens here - back on the scanner!”<stembedurl>https://stocktwits.com/JammyGitTradaz/message/637812831</stembedurl>Another user suggested the stock could return to $5.&nbsp;<stembedurl>https://stocktwits.com/CookieWatcher/message/637811657</stembedurl><a href="https://stocktwits.com/symbol/CTOR">CTOR stock</a> rose nearly 43% so far this year.&nbsp;Get updates to this developing story directly on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Citius Oncology stock (CTOR) jumped nearly 14% at the time of writing.  (Photo credit: Getty Images)

The drug is an IL-2 receptor-directed fusion protein designed to kill IL-2R–expressing cancer cells while depleting regulatory T cells.

Current Price	$0.55
Prev Close	$0.5941
Open	$0.6082
Dividend Yield	0.00%
50-Day Moving Average	$0.8336
Beta	-2.07
Avg. Volume	128,394.78
PE Ratio	-1.25

52-Week High	$1.83
52-Week Low	$0.4912
Market Capitalization	$55.24M
EPS (Annual)	-$0.338
Price to Book	1.56
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

CTOR Fundamentals